Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

Pharmacol Rep. 2018 Oct;70(5):972-980. doi: 10.1016/j.pharep.2018.03.007. Epub 2018 Mar 22.

Abstract

Background: The compound 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), the promising antitumor agent developed in our laboratory was determined to undergo phase I metabolic pathways. The present studies aimed to know its biotransformation with phase II enzymes - UDP-glucuronosyltransferases (UGTs) and its potential to be engaged in drug-drug interactions arising from the modulation of UGT activity.

Methods: UGT-mediated transformations with rat liver (RLM), human liver (HLM), and human intestine (HIM) microsomes and with 10 recombinant human isoenzymes were investigated. Studies on the ability of C-1748 to inhibit UGT were performed with HLM, HT29 colorectal cancer cell homogenate and the selected recombinant UGT isoenzymes. The reactions were monitored using HPLC-UV/Vis method and the C-1748 metabolite structure was determined with ESI-TOF-MS/MS analysis.

Results: Pseudo-molecular ion (m/z 474.1554) and the experiment with β-glucuronidase indicated that O-glucuronide of C-1748 was formed in the presence of microsomal fractions. This reaction was selectively catalyzed by UGT2B7 and 2B17. High inhibitory effect of C-1748 was shown towards isoenzyme UGT1A9 (IC50=39.7μM) and significant but low inhibitory potential was expressed in HT29 cell homogenate (IC50=84.5μM). The mixed-type inhibition mechanism (Ki=17.0μM;Ki'=81.0μM), induced by C-1748 was observed for recombinant UGT1A9 glucuronidation, whereas HT29 cell homogenate resulted in noncompetitive inhibition (Ki=94.6μM).

Conclusions: The observed UGT-mediated metabolism of C-1748 and its ability to inhibit UGT activity should be considered as the potency for drug resistance and drug-drug interactions in the prospective multidrug therapy.

Keywords: Antitumor agent C-1748; Drug-drug interactions; Enzyme inhibition; Glucuronidation; II phase metabolism; UGT.

MeSH terms

  • Animals
  • Biotransformation
  • Cell Line, Tumor
  • Glucuronosyltransferase / antagonists & inhibitors
  • Glucuronosyltransferase / metabolism*
  • Humans
  • Microsomes, Liver / enzymology
  • Nitracrine / analogs & derivatives*
  • Nitracrine / pharmacokinetics
  • Nitracrine / pharmacology
  • Rats
  • UDP-Glucuronosyltransferase 1A9

Substances

  • 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine
  • UGT1A9 protein, human
  • Nitracrine
  • UGT2B7 protein, human
  • Glucuronosyltransferase
  • UDP-Glucuronosyltransferase 1A9